(PDF) Phase 2, Multicenter, Single-Arm Study of Eribulin

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer - United States

doi 10.1016/j.clbc.2014.04.004

Full Text

Open PDF

Abstract

Available in full text

Date

December 1, 2014

Authors

Publisher

Elsevier BV

Related search

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE

English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

English

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2016

English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer

Oncology

2020

English

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

English

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

Cancer Research and Treatment

Cancer Research

Oncology

2018

English

P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer

English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy

English

Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Clinical Breast Cancer

Cancer Research

Oncology

2019

English

Amanote Research

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer - United States

doi 10.1016/j.clbc.2014.04.004

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Results From the First Multicenter, Open-Label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)